Metadherin confers chemoresistance of cervical cancer cells by inducing autophagy and activating ERK/NF-κB pathway

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2433-2440

  Zhang, Jingwei ^a   Zhang, Yunyan ^a   Liu, Shuang ^a   Zhang, Qingmeng ^a   Wang, Yan ^a   Tong, Liping ^a   Chen, Xiaohang ^a   Ji, Yuting ^a   Shang, Qinglong ^a   Xu, Baozhan ^b   Chu, Ming ^a,b   Wei, Lanlan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Autophagy; Cervical cancer; Chemoresistance; Cisplatin; Metadherin

Indexed keywords

CASPASE 3; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ADENOCARCINOMA; ADULT; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER RESISTANCE; CERVICAL ADENOCARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METADHERIN GENE; ONCOGENE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 84881475971     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0794-z     Document Type: Article

References (19)

1. Peiretti M, Zapardied I, Zanagnolo V, et al. Management of recurrent cervical cancer: a review of the literature. Surg Oncol. 2012;21:59-66.
2. Alam MS, Ali A, Mehdi SJ, Alyasiri NS, Kazim Z, Batra S, et al. HPV typing and its relation with apoptosis in cervical carcinoma from Indian population. Tumour Biol. 2012;33:17-22.
3. Yang S, Jia C, Zhu H, Han S. CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis. Tumour Biol. 2012;33:2265-72.
4. Barbisan G, Pérez LO, Contreras A, Golijow CD. TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 2012;33:1549-56.
5. Colombo N, Peiretti M. Critical review of neoadjuvant chemotherapy followed by surgery for locally advanced cervical cancer. Int J Gynecol Cancer. 2010;20:S47-8.
6. Yoo BK, Emdad L, Lee SG, Su ZZ, Santhekadur P, Chen D, et al. Astrocyte elevated gene-1 (AEG-1): a multifunctional regulator of normal and abnormal physiology. Pharmacol Ther. 2011;130:1-8.
7. Yoo BK, Gredier R, Vozhilla N, et al. Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A. 2009;106:12938-43.
8. Emdad L, Sarkar D, Su ZZ, et al. Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res. 2006;66:1509-16.
9. Emdad L, Sarkar D, Su ZZ, et al. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther. 2007;114:155-70.
10. Yoo BK, Emdad L, Su ZZ, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 2009;119:465-77.
11. Yoo BK, Chen D, Su ZZ, et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res. 2010;70:3249-58.
12. Bhutia SK, Kegelman TP, Das SK, et al. Astrocyte elevated gene-1 induces protective autophagy. Proc Natl Acad Sci U S A. 2010;107:22243-8.
13. Wang QS, Li M, Zhang LY, et al. Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology. 2010;57:271-81.
14. Hu G, Wei Y, Kang Y. The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res. 2009;15:5615-20.
15. Zhao Y, Moran MS, Yang Q, Liu Q, Yuan C, Hong S, et al. Metadherin regulates radioresistance in cervical cancer cells. Oncol Rep. 2012;27:1520-6.
16. Sagawa Y, Fujitoh A, Nishi H, Ito H, Yudate T, Isaka K. Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure. Tumour Biol. 2011;32:399-408.
17. Ding ZY, Liu GH, Olsson B, Sun XF. Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells. Tumour Biol. 2013;34:683-93.
18. Hu YL, Jahangiri A, Delay M, Aghi MK. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res. 2012;72:4294-9.
19. Wanichwatanadecha P, Sirisrimangkorn S, Kaewprag J, et al. Transactivation activity of human papillomavirus type 16*l on aldo-keto reductase genes enhances chemoresistance in cervical cancer cells. J Gen Virol. 2012;93:1081-92.